+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibacterial Drugs Market - Global Forecast 2026-2032- Product Image
Antibacterial Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Antibacterial Drugs Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904673
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibacterial Drugs Market is projected to reach USD 56.47 Billion in 2026. It is expected to continue growing at a CAGR of 4.69%, reaching USD 74.53 Billion by 2032.

The antibacterial drugs industry remains a critical pillar of global healthcare as hospitals, outpatient providers, and public health agencies respond to rising antimicrobial resistance, acute bacterial infections, surgical prophylaxis needs, and infection risks in aging and immunocompromised populations.

WHO recognizes antimicrobial resistance as a major global public health threat, and the 2019 Global Research on Antimicrobial Resistance analysis estimated 1.27 million deaths directly attributable to bacterial AMR and 4.95 million deaths associated with bacterial AMR. This makes antibacterial drug discovery, responsible access, antimicrobial stewardship, and resilient antibiotic supply chains central to market competitiveness and public health preparedness.

Transformative Shifts in the Antibacterial Drug Landscape

The antibacterial drugs market is shifting from high-volume broad-spectrum use toward evidence-led, precision antibacterial therapy. Hospitals increasingly prioritize antimicrobial stewardship, rapid diagnostics, susceptibility testing, pathogen surveillance, and real-world outcome data to guide formulary decisions and reduce inappropriate prescribing.

Research and commercialization are concentrating on multidrug-resistant Gram-negative pathogens, methicillin-resistant Staphylococcus aureus, complicated urinary tract infections, hospital-acquired and ventilator-associated pneumonia, bloodstream infections, and combination regimens. Pull incentives, subscription-style reimbursement pilots, and public-private partnerships are gaining importance as traditional antibiotic revenue models remain constrained by short treatment durations and stewardship controls.

Cumulative Impact of Artificial Intelligence on Antibacterial Drugs

Artificial intelligence is increasingly used across antibacterial drug discovery, including target identification, compound screening, molecule optimization, retrosynthesis planning, resistance prediction, clinical trial design, and pharmacovigilance. AI can analyze large chemical libraries, genomic datasets, and microbiology data faster than conventional workflows, improving early-stage prioritization for antibacterial drug development.

The strongest impact comes when AI is paired with high-quality wet-lab validation, curated resistance data, pharmacokinetic and pharmacodynamic modeling, and clinically relevant pathogen panels. Industry leaders are also applying AI to hospital surveillance, demand planning, safety monitoring, and patient stratification while maintaining strict governance around bias, privacy, explainability, and regulatory transparency.

Key Regional Insights for Antibacterial Drugs

Asia-Pacific is a major growth engine for antibacterial drugs due to high infection burden, expanding hospital infrastructure, large generic manufacturing capacity, and rising healthcare access across China, India, Japan, South Korea, Australia, and ASEAN markets. The region is also central to global active pharmaceutical ingredient production and increasingly important for surveillance-led antimicrobial resistance policy. North America remains a premium innovation hub supported by FDA antibacterial development pathways, CDC resistance surveillance, advanced diagnostics adoption, infectious disease research networks, and hospital stewardship programs.

Europe combines mature antibiotic stewardship with EMA regulatory oversight, ECDC surveillance, national action plans, and procurement models that increasingly value access to novel antimicrobials. Latin America, led by Brazil and Mexico, shows sustained demand for affordable antibacterial drugs, stronger hospital infection control, and improved access to quality-assured therapies. The Middle East is supported by GCC healthcare investment, centralized procurement, tertiary-care expansion, and medical tourism, while Africa reflects high unmet need, infectious disease burden, limited laboratory capacity in several settings, and access-focused opportunities aligned with WHO antimicrobial resistance action plans.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are shaped by diverse healthcare systems, rising hospital capacity, cross-border health security priorities, and the need to balance antimicrobial access with stronger stewardship. The GCC benefits from well-funded public healthcare systems, centralized tenders, antimicrobial resistance action plans, and growing demand for advanced hospital anti-infective therapies, particularly in tertiary care settings.

The European Union is defined by harmonized regulation, coordinated AMR surveillance, pharmacovigilance, and strong stewardship policies that influence antibacterial prescribing and procurement. BRICS countries offer scale through large populations, domestic manufacturing depth, and substantial infection-management needs, while also increasing regulatory scrutiny and surveillance capacity. G7 markets drive innovation, clinical guidelines, reimbursement experimentation, and global health financing discussions, while NATO countries increasingly view antibiotic access, medical readiness, stockpiling, and pharmaceutical supply resilience as strategic security priorities.

Key Country Insights in Major Antibacterial Drug Markets

The United States leads in antibacterial innovation, infectious disease trials, advanced hospital purchasing, CDC surveillance, and FDA regulatory pathways, while Canada emphasizes stewardship, quality use, and equitable access through publicly funded healthcare systems. Mexico and Brazil present major Latin American opportunities through high patient volumes, expanding institutional demand, and ongoing efforts to strengthen antimicrobial controls and hospital infection prevention. The United Kingdom, Germany, France, Italy, and Spain are mature European antibacterial drug markets shaped by stewardship, health technology assessment, national prescribing guidelines, hospital formularies, and surveillance-based policy.

Russia retains significant demand for hospital and community antibacterial therapy, supported by domestic treatment needs and public health monitoring. China and India combine large infection burdens, domestic manufacturing strength, expanding healthcare access, and increasing regulatory oversight of antibiotic quality and use. Japan, Australia, and South Korea are advanced markets with strong quality standards, aging populations, active antimicrobial resistance strategies, and demand for differentiated antibacterial therapies targeting resistant bacterial infections in hospital and specialty-care settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize antibacterial candidates with clear clinical differentiation, activity against WHO and CDC priority resistant pathogens, defensible intellectual property, and evidence packages that demonstrate mortality, cure-rate, length-of-stay, safety, or resistance-management value. Linking drugs with rapid diagnostics, susceptibility testing, and stewardship protocols can strengthen adoption and support responsible use.

Organizations should diversify active pharmaceutical ingredient sourcing, invest in quality systems, strengthen shortage-risk monitoring, expand real-world evidence programs, and engage early with regulators, payers, hospitals, and public health agencies. Partnerships with academic groups, diagnostics developers, government funders, and global health organizations can reduce development risk while supporting responsible antibacterial access across high-income and resource-limited settings.

Research Methodology

The executive summary is developed through a structured research methodology combining secondary research, expert interpretation, and cross-validation of public health, regulatory, clinical, and commercial sources. Core references include WHO, CDC, ECDC, FDA, EMA, national health agencies, peer-reviewed journals, clinical trial registries, antimicrobial resistance surveillance programs, treatment guidelines, and public procurement information.

The analysis evaluates antibacterial drug classes, pathogen priorities, regional healthcare dynamics, reimbursement trends, manufacturing risks, stewardship policies, access considerations, and AI-enabled innovation. Insights are triangulated to avoid unsupported claims and to present an evidence-based view of market direction, competitive positioning, regulatory priorities, and strategic opportunities without relying on market sizing or forecast assumptions.

Conclusion

The antibacterial drugs market is entering a decisive period where antimicrobial resistance, hospital infection control, public health preparedness, and pharmaceutical innovation intersect. Demand remains durable, but commercial success depends on solving real clinical problems, improving patient outcomes, and preserving antibiotic effectiveness rather than relying on volume growth alone.

Organizations that combine novel mechanisms, reliable supply, responsible promotion, diagnostic integration, stewardship alignment, and credible real-world evidence will be best positioned. As AI, surveillance, reimbursement reform, and regional access strategies mature, the sector will reward participants that deliver measurable value to patients and health systems while protecting the long-term utility of antibacterial therapy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antibacterial Drugs Market, by Drug Class
7.1. Introduction
7.2. Aminoglycosides
7.2.1. Amikacin
7.2.2. Gentamicin
7.2.3. Streptomycin
7.2.4. Tobramycin
7.3. Beta-Lactams
7.3.1. Carbapenems
7.3.2. Cephalosporins
7.3.3. Monobactams
7.3.4. Penicillins
7.4. Macrolides
7.5. Quinolones
7.6. Sulfonamides
7.7. Tetracyclines
8. Antibacterial Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Topical
9. Antibacterial Drugs Market, by Molecule Type
9.1. Introduction
9.2. Branded
9.3. Generic
10. Antibacterial Drugs Market, by Spectrum Of Activity
10.1. Introduction
10.2. Broad Spectrum
10.3. Narrow Spectrum
11. Antibacterial Drugs Market, by Mechanism of Action
11.1. Introduction
11.2. Cell Wall Inhibitors
11.3. DNA Inhibitors
11.4. Protein Synthesis Inhibitors
12. Antibacterial Drugs Market, by Formulation
12.1. Introduction
12.2. Capsules
12.3. Liquid
12.4. Powder
12.5. Tablets
13. Antibacterial Drugs Market, by Indication
13.1. Introduction
13.2. Respiratory Infections
13.3. Sexually Transmitted Infections
13.4. Skin Infections
13.5. Urinary Tract Infections
14. Antibacterial Drugs Market, by Point of Sale
14.1. Introduction
14.2. Over-The-Counter Drugs
14.3. Prescription Drugs
15. Antibacterial Drugs Market, by Distribution Channel
15.1. Introduction
15.2. Offline
15.2.1. Hospital Pharmacy
15.2.2. Retail Pharmacy
15.3. Online
16. Antibacterial Drugs Market, by Region
16.1. Asia-Pacific
16.2. North America
16.3. Latin America
16.4. Europe
16.5. Middle East
16.6. Africa
17. Antibacterial Drugs Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. Antibacterial Drugs Market, by Country
18.1. United States
18.2. China
18.3. Germany
18.4. India
18.5. United Kingdom
18.6. Canada
18.7. Japan
18.8. France
18.9. Brazil
18.10. Italy
18.11. South Korea
18.12. Mexico
18.13. Australia
18.14. Spain
18.15. Russia
19. Competitive Landscape
19.1. Market Share Analysis, 2025
19.2. FPNV Positioning Matrix, 2025
19.3. Market Concentration Analysis, 2025
19.3.1. Concentration Ratio (CR)
19.3.2. Herfindahl Hirschman Index (HHI)
19.4. Recent Developments & Impact Analysis, 2025
19.5. Product Portfolio Analysis, 2025
19.6. Benchmarking Analysis, 2025
20. Company Profiles
20.1. Abbott Laboratories
20.2. AbbVie Inc.
20.3. Allecra Therapeutics GmbH
20.4. Astellas Pharma Inc.
20.5. AstraZeneca PLC
20.6. Bausch Health Companies Inc.
20.7. Bayer AG
20.8. Bristol-Myers Squibb Company
20.9. Century Pharmaceuticals Ltd.
20.10. Cipla Limited
20.11. Debiopharm Group
20.12. Dr. Reddy’s Laboratories Ltd.
20.13. Eli Lilly and Company
20.14. Entasis Therapeutics by Innoviva, Inc.
20.15. F. Hoffmann-La Roche AG
20.16. GlaxoSmithKline PLC
20.17. Glenmark Pharmaceuticals Limited
20.18. Hikma Pharmaceuticals PLC
20.19. Iterum Therapeutics PLC
20.20. Johnson & Johnson Services, Inc.
20.21. Kyorin Pharmaceutical Co., Ltd.
20.22. Lupin Limited
20.23. Melinta Therapeutics LLC
20.24. Merck & Co., Inc.
20.25. Novartis AG
20.26. Pfizer Inc.
20.27. Sanofi S.A.
20.28. Sumitomo Pharma Co., Ltd.
20.29. Sun Pharmaceutical Industries Limited
20.30. Taj Pharmaceuticals Limited
20.31. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL ANTIBACTERIAL DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTIBACTERIAL DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 27. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 29. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. GLOBAL ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 31. GLOBAL ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ANTIBACTERIAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL AMIKACIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL AMIKACIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL AMIKACIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL GENTAMICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL GENTAMICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL GENTAMICIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL STREPTOMYCIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL STREPTOMYCIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL STREPTOMYCIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TOBRAMYCIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TOBRAMYCIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TOBRAMYCIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL BETA-LACTAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL BETA-LACTAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BETA-LACTAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CARBAPENEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CARBAPENEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CARBAPENEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MONOBACTAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MONOBACTAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MONOBACTAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MACROLIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MACROLIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MACROLIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL QUINOLONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL QUINOLONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL QUINOLONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SULFONAMIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SULFONAMIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SULFONAMIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TETRACYCLINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL TETRACYCLINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL TETRACYCLINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL BRANDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL GENERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL BROAD SPECTRUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL BROAD SPECTRUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL BROAD SPECTRUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NARROW SPECTRUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NARROW SPECTRUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NARROW SPECTRUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL CELL WALL INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL CELL WALL INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CELL WALL INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL DNA INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL DNA INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL DNA INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PROTEIN SYNTHESIS INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PROTEIN SYNTHESIS INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PROTEIN SYNTHESIS INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LIQUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL POWDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL POWDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL POWDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SKIN INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SKIN INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL SKIN INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL OVER-THE-COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 166. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 168. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 169. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 170. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 171. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 172. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 173. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 174. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 175. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 176. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 177. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 178. EUROPE ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 192. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 193. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 194. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 195. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 196. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 198. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 199. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 200. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 201. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 202. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 203. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 204. AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 205. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 206. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 207. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 208. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 209. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 210. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 211. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 212. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 213. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 214. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 215. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 216. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 217. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 218. ASEAN ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 219. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 221. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 222. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 223. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 224. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 225. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 226. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 227. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 228. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 229. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 230. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. GCC ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 245. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 246. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 247. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 248. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 249. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 250. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 251. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 252. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 253. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 254. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 255. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 256. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 257. BRICS ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 258. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 259. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 260. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 261. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 262. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 264. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 265. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 266. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 267. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 268. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 269. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. G7 ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 271. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 272. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 273. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 274. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 275. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 276. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 277. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 278. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 279. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 280. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 281. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 282. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 283. NATO ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 284. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 285. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 287. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 288. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 289. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 290. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 294. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 298. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 299. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 300. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 301. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 302. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 303. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 304. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 305. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 306. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 307. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 308. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 309. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 310. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 311. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 313. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 314. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 315. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 316. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 317. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 318. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 319. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 320. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 321. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 322. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 323. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 324. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 326. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 327. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 328. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 329. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 330. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 331. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 332. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 333. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 334. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 335. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 336. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 337. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 338. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 339. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 340. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 341. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 342. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 343. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 344. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 345. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 346. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 347. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 348. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 349. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 350. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 351. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 352. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2017-2032 (USD MILLION)
TABLE 353. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2017-2032 (USD MILLION)
TABLE 354. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 355. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 356. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2017-2032 (USD MILLION)
TABLE 357. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 358. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY FORMULATION, 2017-2032 (USD MILLION)
TABLE 359. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 360. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2017-2032 (USD MILLION)
TABLE 361. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 362. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 363. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 364. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Allecra Therapeutics GmbH
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Century Pharmaceuticals Ltd.
  • Cipla Limited
  • Debiopharm Group
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Entasis Therapeutics by Innoviva, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Iterum Therapeutics PLC
  • Johnson & Johnson Services, Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Lupin Limited
  • Melinta Therapeutics LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 56.47 Billion
Forecasted Market Value ( USD ) by 2032 $ 74.53 Billion
Compound Annual Growth Rate4.6%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Antibiotics Market - Global Forecast 2026-2032 - Product Image

Antibiotics Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Beta Lactam & Beta Lactamase Inhibitors Market - Global Forecast 2026-2032 - Product Image

Beta Lactam & Beta Lactamase Inhibitors Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Antibacterial Drugs - Global Strategic Business Report - Product Image

Antibacterial Drugs - Global Strategic Business Report

  • Report
  • 244 Pages
  • Global
From
Antibacterial Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033 - Product Image

Antibacterial Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033

  • Report
  • 200 Pages
  • Global
From
Antibacterial Drugs Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Class, Drug Mechanism, Spectrum of Activity, Route of Administration - Product Image

Antibacterial Drugs Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Class, Drug Mechanism, Spectrum of Activity, Route of Administration

  • Report
  • 160 Pages
  • Global
From

About the Antibiotics Market

Aminoglycosides are a class of antibiotics used to treat a wide range of bacterial infections. They are derived from natural sources, such as soil bacteria, and are effective against Gram-negative bacteria. Aminoglycosides work by inhibiting protein synthesis in bacteria, which prevents them from replicating and spreading. They are often used in combination with other antibiotics to treat more serious infections. Aminoglycosides are commonly used in hospitals and other healthcare settings, as well as in the treatment of serious infections in the community. They are also used in veterinary medicine. The aminoglycosides market is highly competitive, with a number of companies offering a range of products. Major players in the market include Merck & Co., Pfizer, Sanofi, Novartis, and Bayer. Other companies in the market include Allergan, AstraZeneca, GlaxoSmithKline, and Eli Lilly. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.